Zimmer Biomet (NYSE:ZBH) Insider Chad Phipps Sells 3,000 Shares of Stock

Posted by George Bondi on Sep 10th, 2026

Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) insider Chad Phipps sold 3,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $94.78 on Thursday. The stock has a market cap of $18.08 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 1.78 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $106.88. The firm’s 50-day simple moving average is $95.33 and its 200 day simple moving average is $91.56.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period in the previous year, the company posted $2.07 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Institutional Investors Weigh In On Zimmer Biomet

Several large investors have recently made changes to their positions in ZBH. California State Teachers Retirement System boosted its stake in Zimmer Biomet by 7,899.1% in the second quarter. California State Teachers Retirement System now owns 26,825,816 shares of the medical equipment provider’s stock valued at $2,309,434,000 after acquiring an additional 26,490,456 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $1,344,282,000. Primecap Management Co. CA purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $328,578,000. Norges Bank bought a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $221,234,000. Finally, Bank of America Corp DE bought a new stake in shares of Zimmer Biomet in the 2nd quarter worth approximately $187,480,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Sanford C. Bernstein upped their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. BMO Capital Markets reissued a “market perform” rating and set a $96.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Canaccord Genuity Group upped their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Finally, Truist Financial increased their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $104.42.

View Our Latest Analysis on ZBH

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.